Compare FLR & BIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLR | BIO |
|---|---|---|
| Founded | 1912 | 1952 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Laboratory Analytical Instruments |
| Sector | Industrials | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 8.0B |
| IPO Year | N/A | N/A |
| Metric | FLR | BIO |
|---|---|---|
| Price | $46.04 | $293.62 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 4 |
| Target Price | $49.57 | ★ $358.50 |
| AVG Volume (30 Days) | ★ 2.6M | 233.6K |
| Earning Date | 02-17-2026 | 02-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1235.20 | N/A |
| EPS | ★ 20.04 | N/A |
| Revenue | ★ $15,587,000,000.00 | $2,557,500,000.00 |
| Revenue This Year | N/A | $1.50 |
| Revenue Next Year | $5.20 | $2.23 |
| P/E Ratio | $2.31 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $29.20 | $211.43 |
| 52 Week High | $57.50 | $368.65 |
| Indicator | FLR | BIO |
|---|---|---|
| Relative Strength Index (RSI) | 59.70 | 34.96 |
| Support Level | $45.22 | $287.46 |
| Resistance Level | $47.37 | $302.59 |
| Average True Range (ATR) | 1.42 | 8.96 |
| MACD | 0.24 | -2.48 |
| Stochastic Oscillator | 71.29 | 15.02 |
Fluor is one of the largest global providers of engineering, procurement, construction, fabrication, operations, and maintenance services.It serves a wide range of end markets, including oil and gas, chemicals, mining, metals, and transportation. The company's business is organized into three core segments: urban solutions, mission solutions, and energy solutions. Fluor generated $16.3 billion in revenue in 2024.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.